Tellus BioVentures

Cantai Therapeutics operates as a developer of drug candidates.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Praeventix is an early-stage biotechnology company dedicated to developing novel therapeutics for bowel diseases and other serotonergic-driven disorders. The company specializes in the discovery and early clinical development of therapeutics that modulate signal transduction, with a primary focus on treating inflammatory bowel diseases and addressing unmet clinical needs. In addition to bowel diseases, Praeventix's research has potential applications in dermatologic, autoimmune, and neurodegenerative conditions, aiming to provide physicians with effective treatment options for chronic pruritus and related disorders.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

Navrogen, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania, founded in 2017. The company specializes in the targeted treatment of cancer by enhancing the immune system's ability to combat tumors. Navrogen develops technology that identifies proteins produced by tumors that suppress the body's humoral immune response, which can hinder both natural immunity and the effectiveness of antibody-based therapies. By assembling a comprehensive database of tumor types that produce these immunosuppressive factors, Navrogen aims to support physicians in overcoming these challenges, thereby improving cancer treatment outcomes.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

TamuroBio is a biotechnology company dedicated to developing innovative therapeutics for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and Type 2 diabetes. The company is focused on its pre-clinical candidate, which aims to sequester lipotoxic products, thereby addressing the underlying causes of these conditions. By targeting the treatment of NASH, TamuroBio seeks to assist patients in preventing chronic liver disease and improving their overall quality of life.

Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies using extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Established in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, the company aims to address dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by blistering. Aegle's proprietary technology isolates EVs in a cell-free manner, allowing for a safer and potentially more cost-effective approach to harnessing the regenerative properties of stem cells. The company’s EV therapy is designed to enhance healing, reduce scarring, and improve the overall appearance of affected tissues. Aegle has received FDA clearance for its Investigational New Drug application for dystrophic epidermolysis bullosa and anticipates entering clinical trials in the near future.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.